Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||FD1921 / 2||- / OT|
Administered by: Other Purchased by: ??
Symptoms: Asthenia, Sinus bradycardia
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Other Medications: FUROSEMIDE; RANEXA; LUVION [CANRENONE]
Preexisting Conditions: Medical History/Concurrent Conditions: Angina pectoris; Aortic stenosis; Decompensation cardiac; Heteroplasia
Diagnostic Lab Data:
CDC 'Split Type': ITPFIZER INC2021704961
Write-up: Marked asthenia and sinus bradycardia with impossibility to assess spO2; Marked asthenia and sinus bradycardia with impossibility to assess spO2; This is a spontaneous report received from a contactable physician downloaded from the Regulatory Authority-WEB. The regulatory authority report number is IT-MINISAL02-741082. An 89-year-old female patient received bnt162b2 (COMIRNATY), intramuscular on 05Jun2021 at age of 89-year-old (Lot Number: FD1921) as dose 2, single for covid-19 immunisation. Medical history included aortic aortic stenosis, decompensation cardiac, heteroplasia all unknown if ongoing and angina pectoris. Patient received 1st dose of bnt162b2 (COMIRNATY) on 23Apr2021 via intramascular for COVID-19 vaccination and no adverse reaction. Concomitant medications included furosemide (FUROSEMIDE) taken for decompensation cardiac; ranolazine (RANEXA) taken for angina pectoris; canrenone (LUVION) taken for decompensation cardiac. The patient experienced marked asthenia and sinus bradycardia with impossibility to assess spo2 on 05Jun2021. The patient died of Marked asthenia and sinus bradycardia with impossibility to assess spO2 on 05Jun2021. It was not reported if an autopsy was performed. Clinical course: Patient suffering from serious pathologies (heart failure, pulmonary heteroplasia, severe aortic stenosis) in precarious health conditions. 1st dose of vaccine 15May2021 (as reported, pending clarification): no adverse reactions 2nd dose of vaccine 05Jun2021: marked asthenia and bradycardia on the same day. At 8.30 pm he was transported by ambulance to the hospital and died during transport. No analyzes or other tests were performed. On 08Jun2021 contacted the reporting physician for clinical report. On 10Jun2021 received clinical report, from the reporter.; Reported Cause(s) of Death: Marked asthenia and sinus bradycardia with impossibility to assess spO2; Marked asthenia and sinus bradycardia with impossibility to assess spO2
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166